Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CFSAN Adverse Event Strategy: Will Notifying Industry Create A 2-Way Road?

This article was originally published in The Tan Sheet

Executive Summary

CFSAN will begin sending letters to companies notifying them when an adverse event report involving one of their products has been received on or after Sept. 16

You may also be interested in...



Trans Fat Labeling Should Help Product Comparisons, FDAer Claims

FDA will conduct an "educational campaign" over the next couple of years to teach consumers about trans fat and what to consider when buying products that contain the substance, according to San Francisco District Office Public Affairs Specialist Janet McDonald, PhD

Trans Fat Labeling Should Help Product Comparisons, FDAer Claims

FDA will conduct an "educational campaign" over the next couple of years to teach consumers about trans fat and what to consider when buying products that contain the substance, according to San Francisco District Office Public Affairs Specialist Janet McDonald, PhD

Trans Fat Labeling Should Help Product Comparisons, FDAer Claims

FDA will conduct an "educational campaign" over the next couple of years to teach consumers about trans fat and what to consider when buying products that contain the substance, according to San Francisco District Office Public Affairs Specialist Janet McDonald, PhD

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094470

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel